BB10 Peptide Blend COA: What Documentation Should Include for Co-Lyophilized BPC-157 + TB500

This article is intended for laboratory professionals, raw material researchers, and quality assurance teams working with peptide preparations. All products described are supplied for research, laboratory, and development use only.

Why COA Verification Is Different for a Two-Component Blend

For single-compound peptide raw materials, certificate of analysis (COA) review is straightforward: one HPLC purity result, one mass spectrometry identity confirmation, moisture content, and a batch number. A co-lyophilized two-component preparation like BB10 — which contains BPC-157 (CAS 137525-51-0) and TB500 / Thymosin Beta-4 Acetate (CAS 885340-08-9) in a single lyophilized matrix — requires documentation that accounts for both compounds independently.

A COA that reports a single combined purity figure without distinguishing the two components does not meet the analytical standard for a two-compound preparation. This guide outlines specifically what a complete BB10 COA should include, and what to watch for when evaluating supplier documentation.

The Five Core Elements of a Complete BB10 COA

1. Dual HPLC Purity — Separate Values for Each Component

The most critical element of a two-component COA is resolved purity data for each compound. For BB10, this means:

• BPC-157 (CAS 137525-51-0): HPLC purity ≥99%
• TB500 / Thymosin Beta-4 Acetate (CAS 885340-08-9): HPLC purity ≥99%

These values must be reported independently, not as a single combined percentage. A properly conducted HPLC analysis of a co-lyophilized BPC-157 + TB500 preparation will produce resolved peaks for both compounds — BPC-157 (MW ~1419 Da, pentadecapeptide) and TB500 (MW ~4963 Da, 43-amino-acid peptide) have sufficiently different molecular weights and sequences to be resolved under standard reversed-phase HPLC conditions. If a supplier provides a chromatogram in which the two compounds are not labeled or identified separately, the analytical documentation is incomplete.

2. Dual Mass Spectrometry Identity Confirmation

Identity confirmation by mass spectrometry should be provided for both CAS numbers. Acceptable formats include:

• ESI-MS or MALDI-TOF showing the observed molecular ion or charge-state envelope for each compound
• The expected molecular weight for BPC-157 is approximately 1419.5 Da (monoisotopic)
• The expected molecular weight for TB500 is approximately 4963.5 Da (average, for the acetate salt form)

A COA that provides MS data for only one of the two components — or that provides no MS data at all — does not confirm the identity of the co-lyophilized preparation as a whole. Both CAS numbers should be traceable in the analytical documentation.

3. Blend Ratio Verification

BB10 is defined as a 1:1 weight ratio of BPC-157 to TB500, with 5 mg of each compound per vial (10 mg total). The COA should state the per-component contribution explicitly — either as a weight per vial or as a verified ratio derived from HPLC peak area data.

This matters because a co-lyophilized preparation may vary from its intended ratio if the compounding step prior to lyophilization is not tightly controlled. Blend ratio verification from HPLC peak areas is the standard method for confirming that the finished preparation meets the 5mg + 5mg specification.

4. Karl Fischer Moisture Content

Residual moisture is a critical stability parameter for lyophilized peptide preparations. A properly lyophilized peptide product should show moisture content of ≤5% by Karl Fischer titration. Higher moisture levels suggest an incomplete or suboptimal lyophilization cycle, which can accelerate peptide degradation during storage.

This specification applies to the co-lyophilized BB10 preparation in the same way it applies to single-compound lyophilized raw materials. If a supplier’s COA does not include moisture data, this is a gap in the analytical package.

5. Batch Number and Traceability

A co-lyophilized preparation should carry a single batch number that covers the full manufacturing process — from the compounding of the two-component solution through the lyophilization step. This allows any quality issue to be traced back to a specific manufacturing run.

Be cautious of COAs where BPC-157 and TB500 each carry separate batch numbers with no shared co-lyophilized batch identifier — this may indicate that the product is a mechanical blend of separately lyophilized powders rather than a true co-lyophilized preparation.

Red Flags in COA Documentation for Co-Lyophilized Blends

When reviewing supplier documentation for BB10 or similar co-lyophilized blends, the following are markers of incomplete or inadequate quality documentation:

• Single combined purity percentage — e.g., “Purity: 98.5%” with no breakdown by component. This figure cannot be attributed to either BPC-157 or TB500 individually.
• MS data for only one compound — Identity confirmation of a two-compound preparation requires MS data for both CAS numbers.
• No blend ratio data — The COA does not state the per-component contribution or verify the 1:1 ratio.
• Two separate single-compound COAs submitted instead of one co-lyophilized COA — This is a strong indicator that the product is a mechanical blend of pre-lyophilized individual powders, not a co-lyophilized preparation.
• No moisture content — Absence of Karl Fischer data removes a key stability indicator from the analytical package.

Questions to Ask a Supplier Before Ordering

For laboratory teams conducting supplier qualification for BB10 or similar co-lyophilized preparations, the following questions provide a structured starting point:

1. Is this product a true co-lyophilized preparation, or a mechanical blend of individually lyophilized BPC-157 and TB500 powders?
2. Does the COA report separate HPLC purity values for BPC-157 and TB500?
3. Is MS identity data available for both CAS numbers (137525-51-0 and 885340-08-9)?
4. How is the 1:1 blend ratio verified in the finished preparation?
5. What is the typical Karl Fischer moisture result for this product?

These are standard due diligence questions for any two-component lyophilized raw material. A qualified supplier should be able to answer all five without hesitation and provide the corresponding documentation.

Requesting Documentation Before Purchase

For first-time orders of any co-lyophilized peptide blend, requesting a COA preview prior to placing an order is standard practice in raw material procurement for research applications. A preview COA allows the receiving laboratory to verify that the analytical package meets their internal standards before committing to an order.

Vitaconin provides dual-component COA documentation with all BB10 orders — including separate HPLC purity values for BPC-157 and TB500, dual MS identity confirmation, blend ratio verification, and Karl Fischer moisture data. COA previews are available on request.

→ BB10 Lyophilized Powder — Specifications and Inquiry
→ Lyophilized Peptide Powder Catalog

References:
[1] ICH Harmonised Guideline Q6A: Specifications — Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. International Council for Harmonisation, 1999.
[2] Görög S. The changing face of pharmaceutical analysis. TrAC Trends in Analytical Chemistry. 2007;26(1):12–17.